SCHEMBL4133929

SCHEMBL4133929

CCCCCCCC/C=C\CCCCCCCC(=O)[N+](C)(C)C(=O)CCCCCCC/C=C\CCCCCCCC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 6/20 0.65
TERT O14746 3/20 0.63
PTPN1 P18031 3/20 0.63
PPARG P37231 3/20 0.63
PPARD Q03181 3/20 0.63
PPARA Q07869 3/20 0.63
CYP1A2 P05177 2/20 0.63
MAPT P10636 2/20 0.63
CYP2C19 P33261 2/20 0.63
BLM P54132 2/20 0.63
HSD17B10 Q99714 2/20 0.63
FABP4 P15090 2/20 0.63
FAAH O00519 2/20 0.63
KMT2A Q03164 2/20 0.63
F7 P08709 2/20 0.63
F3 P13726 2/20 0.63
GMNN O75496 1/20 0.63
USP2 O75604 1/20 0.63
LMNA P02545 1/20 0.63
POLB P06746 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7045888 1.00 FABP3 (0.65) FABP3TERTPTPN1PPARGPPARD
SCHEMBL1626315 1.00 FABP3 (0.65) FABP3TERTPTPN1PPARGPPARD
Hydrochloric Acid SCHEMBL25963 0.98 FABP3 (0.62) FABP3TERTPTPN1PPARGPPARD
Propane SCHEMBL480215 0.98 FABP3 (0.62) FABP3TERTPTPN1PPARGPPARD
Water SCHEMBL3915284 0.98 FABP3 (0.62) FABP3TERTPTPN1PPARGPPARD
Hydrochloric Acid SCHEMBL35815 0.98 FABP3 (0.62) FABP3TERTPTPN1PPARGPPARD
Bromide SCHEMBL3414482 0.98 FABP3 (0.62) FABP3TERTPTPN1PPARGPPARD
Iodide SCHEMBL6695071 0.98 FABP3 (0.62) FABP3TERTPTPN1PPARGPPARD
Water SCHEMBL3915280 0.98 FABP3 (0.62) FABP3TERTPTPN1PPARGPPARD
Bromide SCHEMBL28018195 0.98 FABP3 (0.62) FABP3TERTPTPN1PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025080869-A1 PANCREATIC CANCER IMMUNOTHERAPY USING CATIONIC LIPID AND POLYMER NANOCARRIERS FOR CO-DELIVERY OF KRAS NEOANTIGENS AND STING AND/OR OTHER IMMUNOMODULATORS TO BOOST THE CANCER IMMUNITY CYCLE AND TREAT LIVER METASTASIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-04-17 WO claimed
CN-119424690-A Electronegativity-adjustable contrast agent film forming agent composition, contrast agent and preparation method thereof 北京大学 2025-02-14 CN claimed
EP-4342929-A1 POLYETHYLENE GLYCOL LIPID AND USE THEREOF Jenkem Technology Co. Ltd. (Tianjin) (CN) 2024-03-27 EP claimed
EP-2833869-B1 METHOD OF PREPARING COMPOSITION FOR DELIVERING AN ANIONIC DRUG SAMYANG BIOPHARMACEUTICALS (KR) 2020-10-28 EP claimed
EP-2729124-B1 CATIONIC OIL-IN-WATER EMULSIONS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2018-10-24 EP claimed
EP-2590625-B1 CATIONIC OIL-IN-WATER EMULSIONS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2017-09-20 EP claimed
EP-0832271-B1 LIPID-NUCLEIC ACID PARTICLES PREPARED VIA A HYDROPHOBIC LIPID-NUCLEIC ACID COMPLEX INTERMEDIATE AND USE FOR GENE TRANSFER INEX PHARMACEUTICAL CORP (CA) 2004-12-22 EP claimed
CN-120129751-A Novel secretion signal peptide 得克萨斯大学体系董事会 2025-06-10 CN disclosed
WO-2025080869-A1 PANCREATIC CANCER IMMUNOTHERAPY USING CATIONIC LIPID AND POLYMER NANOCARRIERS FOR CO-DELIVERY OF KRAS NEOANTIGENS AND STING AND/OR OTHER IMMUNOMODULATORS TO BOOST THE CANCER IMMUNITY CYCLE AND TREAT LIVER METASTASIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-04-17 WO disclosed
CN-119424690-A Electronegativity-adjustable contrast agent film forming agent composition, contrast agent and preparation method thereof 北京大学 2025-02-14 CN disclosed
WO-2024041372-A1 BRANCHED POLYPEPTIDE VECTOR FOR EFFECTIVELY DELIVERING NUCLEIC ACIDS AND VARIANT THEREOF 苏州慧疗生物医药科技有限公司 2024-02-29 WO disclosed
US-11802144-B2 Circular RNA compositions and methods ORNA THERAPEUTICS, INC. (US) 2023-10-31 US disclosed
US-20230331806-A1 CIRCULAR RNA COMPOSITIONS AND METHODS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2023-10-19 US disclosed
CN-107266391-A Amine cation lipid and application thereof 迪克纳制药公司 2017-10-20 CN disclosed
CN-103987847-B amine cationic lipids and uses thereof 迪克纳制药公司 2017-06-16 CN disclosed
CN-106687120-A Plant sRNA extract for use as an immunosuppressive agent 埃德蒙马赫基金会 2017-05-17 CN disclosed
US-9469596-B2 Method for removing quaternary salt ARAKAWA CHEMICAL INDUSTRIES, LTD. (JP) 2016-10-18 US disclosed
US-20150031918-A1 METHOD FOR REMOVING QUATERNARY SALT ARAKAWA CHEMICAL INDUSTRIES, LTD. (JP) 2015-01-29 US disclosed
US-20090060992-A1 Preparation of magneto-vesicles with DOPE/DDAB layers UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., 2009-03-05 US disclosed
US-20080107649-A1 Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide PEVION BIOTECH LTD. (CH) 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080107649-A1 Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide IAPP, APP, BACE1 FABP3 1904/4885TERT 1306/4885PTPN1 1678/4885
US-20230331806-A1 CIRCULAR RNA COMPOSITIONS AND METHODS RBM17, RTCB, RBM22 FABP3 2872/4885TERT 134/4885PTPN1 1940/4885
US-11802144-B2 Circular RNA compositions and methods RBM17, RTCB, RBM22 FABP3 2872/4885TERT 134/4885PTPN1 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.